This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, Y.
Right arrow Articles by Leppla, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, Y.
Right arrow Articles by Leppla, S. H.

 Previous Article  |  Next Article 

Infect Immun, July 1998, p. 3447-3448, Vol. 66, No. 7
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Study of Immunization against Anthrax with the Purified Recombinant Protective Antigen of Bacillus anthracis

Yogendra Singh,1,* Bruce E. Ivins,2 and Stephen H. Leppla3

Centre for Biochemical Technology, Delhi, India,1 and Bacteriology Division, U.S. Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick,2 and Oral Infection and Immunity Branch, National Institute of Dental Research, National Institutes of Health, Bethesda,3 Maryland

Received 30 January 1998/Returned for modification 6 March 1998/Accepted 16 April 1998

Protective antigen (PA) of anthrax toxin is the major component of human anthrax vaccine. Currently available human vaccines in the United States and Europe consist of alum-precipitated supernatant material from cultures of toxigenic, nonencapsulated strains of Bacillus anthracis. Immunization with these vaccines requires several boosters and occasionally causes local pain and edema. We previously described the biological activity of a nontoxic mutant of PA expressed in Bacillus subtilis. In the present study, we evaluated the efficacy of the purified mutant PA protein alone or in combination with the lethal factor and edema factor components of anthrax toxin to protect against anthrax. Both mutant and native PA preparations elicited high anti-PA titers in Hartley guinea pigs. Mutant PA alone and in combination with lethal factor and edema factor completely protected the guinea pigs from B. anthracis spore challenge. The results suggest that the mutant PA protein may be used to develop an effective recombinant vaccine against anthrax.

* Corresponding author. Mailing address: Centre for Biochemical Technology, Mall Road, Near Jubilee Hall, Delhi 110 007, India. Phone: (91) 11-7256157. Fax: (91) 11-725 7471. E-mail: cbt{at}delnet.ren.nec.in.

Infect Immun, July 1998, p. 3447-3448, Vol. 66, No. 7
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Cao, S., Guo, A., Liu, Z., Tan, Y., Wu, G., Zhang, C., Zhao, Y., Chen, H. (2009). Investigation of New Dominant-Negative Inhibitors of Anthrax Protective Antigen Mutants for Use in Therapy and Vaccination. Infect. Immun. 77: 4679-4687 [Abstract] [Full Text]  
  • Gauthier, Y. P., Tournier, J.-N., Paucod, J.-C., Corre, J.-P., Mock, M., Goossens, P. L., Vidal, D. R. (2009). Efficacy of a Vaccine Based on Protective Antigen and Killed Spores against Experimental Inhalational Anthrax. Infect. Immun. 77: 1197-1207 [Abstract] [Full Text]  
  • Xu, Q., Zeng, M. (2008). Detoxified Lethal Toxin as a Potential Mucosal Vaccine against Anthrax. CVI 15: 612-616 [Abstract] [Full Text]  
  • Bielinska, A. U., Janczak, K. W., Landers, J. J., Makidon, P., Sower, L. E., Peterson, J. W., Baker, J. R. Jr. (2007). Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects against Bacillus anthracis Spore Challenge. Infect. Immun. 75: 4020-4029 [Abstract] [Full Text]  
  • Mohamed, N., Clagett, M., Li, J., Jones, S., Pincus, S., D'Alia, G., Nardone, L., Babin, M., Spitalny, G., Casey, L. (2005). A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized Bacillus anthracis Spore Challenge. Infect. Immun. 73: 795-802 [Abstract] [Full Text]  
  • Barth, H., Aktories, K., Popoff, M. R., Stiles, B. G. (2004). Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins. Microbiol. Mol. Biol. Rev. 68: 373-402 [Abstract] [Full Text]  
  • Marcus, H., Danieli, R., Epstein, E., Velan, B., Shafferman, A., Reuveny, S. (2004). Contribution of Immunological Memory to Protective Immunity Conferred by a Bacillus anthracis Protective Antigen-Based Vaccine. Infect. Immun. 72: 3471-3477 [Abstract] [Full Text]  
  • Musson, J. A., Walker, N., Flick-Smith, H., Williamson, E. D., Robinson, J. H. (2003). Differential Processing of CD4 T-cell Epitopes from the Protective Antigen of Bacillus anthracis. J. Biol. Chem. 278: 52425-52431 [Abstract] [Full Text]  
  • Lee, J. S., Hadjipanayis, A. G., Welkos, S. L. (2003). Venezuelan Equine Encephalitis Virus-Vectored Vaccines Protect Mice against Anthrax Spore Challenge. Infect. Immun. 71: 1491-1496 [Abstract] [Full Text]  
  • Reuveny, S., White, M. D., Adar, Y. Y., Kafri, Y., Altboum, Z., Gozes, Y., Kobiler, D., Shafferman, A., Velan, B. (2001). Search for Correlates of Protective Immunity Conferred by Anthrax Vaccine. Infect. Immun. 69: 2888-2893 [Abstract] [Full Text]  
  • Cirino, N. M., Sblattero, D., Allen, D., Peterson, S. R., Marks, J. D., Jackson, P. J., Bradbury, A., Lehnert, B. E. (1999). Disruption of Anthrax Toxin Binding with the Use of Human Antibodies and Competitive Inhibitors. Infect. Immun. 67: 2957-2963 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»